Treace Medical Concepts, Inc. (TMCI) stock plummeted 5.04% in Friday's intraday trading session after the company's latest earnings call raised concerns over its future growth prospects.
The medical device company reported strong fourth-quarter results, with revenue growing 10.4% year-over-year to $68.7 million, driven by increased adoption of its newer technologies and an increase in active surgeons. However, the company's guidance for 2025 revenue and profitability fell short of expectations.
Treace Medical expects revenue growth of just 7% to 10% in 2025, with revenue ranging from $224 million to $230 million. The company also guided for breakeven adjusted EBITDA for the full year, which some analysts viewed as underwhelming given the company's focus on profitability and expense management.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。